INTRODUCTION
PCR-based whole-genome amplification (WGA) has the goal of generating microgram quantities of genome-representative DNA from picogram or nanogram amounts of starting material. This amplification should introduce little, or ideally no, representational bias. In contrast to other techniques for WGA, PCR-based methods are generally less affected by DNA quality and are more applicable to DNA extracted from various sources (fixed and fresh tissues). Ligation-mediated PCR techniques involve ligating an adaptor sequence onto a "representation" of DNA molecules, generated following enzymatic digestion, random shearing, or chemical cleavage. Single-cell comparative genomic hybridization (SCOMP), described in this protocol, is a form of ligation-mediated PCR that was specifically designed for WGA of extremely limited sources of genomic DNA. The reaction volume is purposely kept to a minimum, and all buffers are optimized to eliminate the need to purify the reaction between steps. In addition, the entire reaction is performed in a single tube. This avoids initial template loss and reduces the risk of PCR contamination. SCOMP begins by converting the genome to a high-complexity representation with a fragment size of <2 kb by digesting with the restriction enzyme MseI. This results in a smear in the range of 100-1500 bp. Following enzyme digestion, adaptors containing specific primer sequences (specific to the restriction enzyme used) are ligated onto the ends of the genomic DNA and amplified in a high-stringency PCR. This results in a smear of PCR products in the range of 100-1500 bp, which can be visualized by agarose gel electrophoresis.
RELATED INFORMATION
When implementing WGA in the laboratory, it is important to assess the entire experimental process closely, including sample collection, fixation, storage, and initial DNA extraction procedures, as all of these factors can affect DNA quality and thus have some bearing on the selection of the WGA technique. When using WGA, it is important first to validate the method selected and to become proficient in the technique before applying it to actual samples. Irrespective of the method selected, it is essential to establish that the results generated from the amplified DNA are indistinguishable from the results obtained from the original genomic DNA.
The DNA that can be amplified by PCR-based WGA includes DNA extracted from fixed, frozen, or archival tissue; whole blood; buccal swabs; single cells; sorted chromosomes; and laser-capture microdissected tissue (for microdissection of tissues embedded in paraffin, the sections must be deparaffinized prior to microdissection). Genomic DNA may be extracted using a variety of commercially available methods such as the QIAmp DNA mini-kit (QIAGEN). Fixation of tissues can introduce sequence variations and reduce overall DNA quality. When studying such tissues, prior examination of the DNA by agarose gel electrophoresis will help determine the DNA quality. The amplified DNA produced is suitable for a range of downstream genetic assays and thus has the potential for use not only in academic research, but also in commercial, forensic, and diagnostic laboratories.
SCOMP was first reported by Klein et al. (1999) 
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If several SCOMP reactions are going to be generated for subsequent analysis (i.e., more than 2-3 µg is required), perform a larger volume digestion (Step 1), and aliquot it prior to
Step 5.
Combine the following reagents:
information about genetic analysis using genomic representation, see Lucito et al. (1998 
Prepare an adaptor for each sample from
Step 4, including the negative control.
6. To form the adaptor complexes, incubate the sample using a step-down program on a thermal cycler going from 65°C to 15°C, ramping at 1°C/min.
7.
Leaving the samples at 15°C, add to each reaction: 14. Clean each sample using the QIAquick PCR purification kit according to the manufacturer's instructions, but elute the PCR products in 50 µL of H 2 O.
If higher concentrations are required for downstream applications, the elution volume can be decreased from 50 to 30 µL, as recommended by QIAGEN.
15. Quantify the products using spectrophotometry.
See Troubleshooting.
TROUBLESHOOTING
Problem: There is amplification in the negative control.
[Step 13.ii]
Solution: Due to the manipulation of PCR products in all PCR-based WGA methods, the reactions can easily be contaminated. If negative controls produce a DNA smear, several steps can be tried to eliminate this:
• Repeat using fresh reagents.
• Use filtered tips to avoid introduction of contaminants via aerosol from the pipette.
• Physically separate the areas in the laboratory where reactions are set up. Prepare and pipette the PCR mixture at one bench, and then add the DNA to the reaction in a different location in the laboratory. Also, use different pipettes for reaction preparation and pipetting of DNA.
• Aliquot all reaction constituents; if an aliquot becomes contaminated, only that aliquot will be lost and not the entire stock.
Problem: Unpredictable amplification is observed.
Solution: A positive control (such as starting with 50 ng of good-quality genomic DNA) can be used to ensure that the reaction is working optimally. In addition:
• Store small aliquots of dNTPs and oligonucleotides, because repeated freeze/thaw cycles of a single stock can affect the integrity of these reagents and thereby affect the efficiency of WGA.
• The starting concentration of DNA is crucial. Best results are obtained when starting with 10 ng (or more) of DNA extracted from fresh tissue/blood or 100 ng of DNA extracted from fixed tissue. Lower amounts of DNA (<10 ng from fresh tissue or <100 ng from fixed tissue) will generate amplification products, but results obtained in downstream applications may not be faithful to the result that would have been obtained from nonamplified DNA.
• In ligation-mediated PCR techniques, lack of amplification or poor amplification may be due to problems with either the DNA or the adaptor ligation. For the former, always include a positive control of 10-100 ng of good-quality, high-molecular-weight DNA. If this sample produces good results, the assay problems are a product of the DNA sample under investigation. However, if the positive control does not amplify, it suggests a problem with the reaction constituents or the thermal cycling. In such cases, use fresh aliquots of reagents, and repeat the experiment. If the problem still persists, it may be necessary to order fresh reagents.
Problem:
The amplification smear contains smaller DNA fragments than expected.
[Step 13.ii]
Solution: The efficiency of amplification is dependent on the quality of the starting DNA, and the size of the amplification products is also template-dependent. Tissue fixation causes degradation of template DNA within the sample. If the template is degraded, as is DNA from formalin-fixed, paraffin-embedded material, the smear will be smaller in size. Unfortunately, there is no way of improving this; thus care must be taken when using such products for downstream applications, because there may be more bias in these samples. Although PCR-based WGA is tolerant to mild or moderate DNA degradation and will amplify DNA with an average length of~200 bp, in this case it is essential to use increased quantities of starting DNA (100 ng) to guarantee a satisfactory yield of final product. Moderate to severe degradation will reduce WGA efficiency and subsequently decrease the quality of results obtained in downstream applications.
Problem: There is insufficient DNA for downstream reactions.
[ 
DISCUSSION
The PCR products resulting from SCOMP have been used for several downstream applications, including chromosomal comparative genomic hybridization (CGH) (Klein et al. 1999) , array CGH (Ghazani et al. 2006) , loss of heterozygosity (Klein et al. 1999) analysis, and direct sequencing (Klein et al. 1999) . Both chromosomal CGH and array CGH analysis require the SCOMP products to be labeled in an additional reaction with appropriate dyes. When using SCOMP products for a comparative analysis (test and control), it is essential to treat both the DNA of interest and the control genomic DNA in the same manner. Because SCOMP reduces the genome to only a representation, it is important that control DNA is also a representation and that the control DNA be of similar quality to the DNA of interest. For example, if the DNA of interest was extracted from formalin-fixed, paraffin-embedded material, then the control "normal" DNA should also be from this source and preferably from the same patient. Pooling several replicate SCOMP reactions from the same sample may also help to reduce any bias that may be introduced in the PCR amplification step.
